ISDA

Entry Detail

PDB ID:

4BGE

Keywords:

OXIDOREDUCTASE

Title:

Crystal structure of InhA(S94A) mutant in complex with pyridomycin

Biological Source:

Source Organism:

Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)

Host Organism:

Escherichia coli BL21(DE3)

PDB Version:

Deposition Date:

2013-03-26

Release Date:

2013-12-04

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.25 Å

R-Value Free:

0.27

R-Value Work:

0.23

R-Value Observed:

0.24

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Enoyl-[acyl-carrier-protein] reductase [NADH]
Mutations:S94A
Chain IDs:A, B, C, D, E, F
Chain Length:269
Number of Molecules:6
Biological Source:Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)

UniProt ID:P9WGR1 Pfam ID:PF13561 EC:1.3.1.118

Ligand Molecules

PYW

Primary Citation

Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA.

Hartkoorn, R.C, Pojer, F, Read, J.A, Gingell, H, Neres, J, Horlacher, O.P, Altmann, K.H, Cole, S.T.Show

Nat. Chem. Biol. 10 96 98 (2014)

PMID: 24292073 DOI: 10.1038/nchembio.1405

Abstact

Pyridomycin, a natural product with potent antituberculosis activity, inhibits a major drug target, the InhA enoyl reductase. Here, we unveil the co-crystal structure and unique ability of pyridomycin to block both the NADH cofactor- and lipid substrate-binding pockets of InhA. This is to our knowledge a first-of-a-kind binding mode that discloses a new means of InhA inhibition. Proof-of-principle studies show how structure-assisted drug design can improve the activity of new pyridomycin derivatives.

Legend

Protein

Chemical

Disease

Primary Citation of related structures